Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer.

Autor:	Karlberg M; Department of Oncology and Pathology, CCK R8:03, Karolinska University Hospital, S-171 76 Stockholm, Sweden., Ohrling K, Edler D, Hallström M, Ullén H, Ragnhammar P
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2010 Feb; Vol. 30 (2), pp. 645-51.
Abstrakt:	Aim: To investigate thymidylate synthase (TS) expression in primary colorectal cancer (CRC) as a prognostic and predictive marker of benefit for adjuvant chemotherapy. Patients and Methods: TS expression was immuno0-histochemically (IHC) assessed on tumors from 1,389 patients with stage II and III CRC randomly assigned to either surgery alone or surgery plus 5-fluorouracil (5-FU)-based adjuvant chemotherapy. Results: In the subgroup treated with surgery alone (n=708), TS expression was prognostic using the classification of TS 0-1 versus 2-3 (p=0.045) as well as TS classified as 0-2 versus 3 (p=0.002). A high TS expression was associated with a shorter overall survival. Among patients with TS grade 3 (n=460), the subgroup treated with adjuvant chemotherapy had a significant longer OS (p=0.005). Conclusion: In this study TS, immunohistochemically assessed, is a prognostic factor in CRC patients treated with surgery alone. Patients with the highest level of TS expression (grade 3) had an improved clinical outcome following adjuvant 5-FU-based chemotherapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu